Products

Sulfanilamide (4-aminobenzenesulfonamide) is the foundational compound of the sulfonamide antibiotic class, featuring a benzene ring with an amino group (-NH₂) at the para position and a sulfonamide group (-SO₂NH₂) at the opposite position.

Azithromycin is a semi‑synthetic 15‑membered macrolide antibiotic belonging to the azalide subclass, derived from erythromycin A through a Beckman rearrangement. The molecule has the molecular formula C₃₈H₇₂N₂O₁₂ and a molecular weight of 748.98 g/mol .

Clascoterone (cortexolone 17α-propionate, CB-03-01) is a first-in-class topical androgen receptor antagonist with a peripherally selective mechanism of action. Structurally, Clascoterone is a synthetic steroid derived from cortexolone (11-deoxycortisol), featuring a propionate ester at the C17α position and a 2-hydroxyacetyl side chain at C17. This unique molecular architecture enables Clascoterone to act as a potent androgen antagonist that is rapidly metabolized upon systemic absorption, thereby limiting systemic androgenic or antiandrogenic effects while maintaining robust local activity in the skin.

Abrocitinib is a small-molecule Janus kinase (JAK) 1 inhibitor approved for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents. Chemically, Abrocitinib selectively inhibits JAK1, modulating the JAK-STAT signalling pathway that plays a key role in the pathogenesis of atopic dermatitis. As the active pharmaceutical ingredient in CIBINQO®, Abrocitinib provides a targeted oral therapy for patients who are candidates for systemic therapy.

Sebetralstat is a potent and selective small-molecule plasma kallikrein inhibitor developed as the first oral, on-demand treatment for acute attacks of hereditary angioedema (HAE) . Chemically, Sebetralstat (also known as KVD900) inhibits plasma kallikrein, the enzyme responsible for converting high-molecular-weight kininogen to bradykinin, the key mediator of angioedema .

Pritelivir is a first-in-class, orally bioavailable viral helicase-primase inhibitor in development for the treatment of herpes simplex virus (HSV) infections, particularly in immunocompromised patients with acyclovir-refractory disease . Chemically, Pritelivir targets the viral helicase-primase complex, a novel mechanism of action distinct from nucleoside analogues like acyclovir .